Here Comes Sun’s US Cost-Saving Gleevec Generic
This article was originally published in PharmAsia News
Executive Summary
India’s Sun Pharma has launched its generic version of Novartis' blockbuster anticancer Gleevec in the US at savings of around 30%, putting the spotlight on the specialty segment which is probably, for the first time, witnessing genericization of such a high cost therapy.
You may also be interested in...
Novartis Builds On Its Legacy With Scemblix Approval For CML
US FDA approval means a new commercial opportunity in CML, where despite the success of older medicines, patients still fail on therapy.
Express Scripts Projects Higher Spending In Inflammation, Diabetes, Cancer
The three most expensive drug categories, on a per-member/per-year basis for the PBM's clients, increased by 19% or more in 2016, and similar growth is expected in the next three years. Per-patient spending on HCV drugs, however, declined by 34% last year.
India Q1 Results Preview: Exclusivity, Compliance Are Key Talking Points
First-quarter results of frontline Indian firms are expected to be a mixed bag as some are boosted by launches of products with marketing exclusivity in the US, while others are weighed down by increased competition and pricing erosion in the base business. Updates on compliance efforts at facilities and evolving regulations in India – the ban on certain fixed-dose combinations and controversial pricing orders – are other key issues to look out for.